Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating YL205, a drug given by intravenous infusion, in patients with advanced solid tumors. This multicenter, open-label phase III study in China aims to assess the safety, tolerability, pharmacokinetics how the drug moves through the body, and preliminary effectiveness of YL205. Eligible patients have advanced solid tumors that overexpress Napi2B and include cancers such as ovarian, non-squamous non-small cell lung, renal cell, and endometrial cancer. Participants receive YL205 as a lyophilized powder reconstituted for intravenous infusion at a dose of 160 mg per vial. Treatment is given once every three weeks in cycles, with dose levels adjusted during different study phases dose escalation phase Ia, dose expansion phase Ib, and cohort expansion phase II. The study evaluates at least two dose levels and the recommended phase 2 dose RP2D. Throughout approximately 36 months, participants are closely monitored for dose-limiting toxicities, treatment-emergent adverse events, and serious adverse events. Researchers assess tumor response using RECIST v1.1 criteria, including overall response rate, disease control rate, duration and depth of response, progression-free survival, and overall survival. Pharmacokinetic parameters like AUC, Cmax, and half-life are also measured. Patients undergo tumor sampling and radiological evaluations to track treatment effects and safety.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and early activity of RO7656594 in adult male participants with advanced or metastatic prostate cancer. This phase 1 study aims to find recommended doses and regimens for RO7656594 for future studies. Participants have advanced prostate adenocarcinoma without small-cell or neuroendocrine features and have undergone prior therapies including androgen receptor-targeted agents and taxane chemotherapy or are ineligiblerefuse taxane treatment. Participants receive RO7656594 orally at specified doses on certain days within each 28-day cycle. The study includes a dose escalation phase where doses increase in successive groups until a threshold is reached, followed by an expansion phase where participants receive doses at or below the maximum tolerated or administered dose. Treatment continues with monitoring for adverse events and dose-limiting toxicities. During the study, participants are monitored for side effects and drug levels in the blood over up to 24 months from the first dose. Researchers measure adverse events, dose-limiting toxicities during the first cycle, and prostate-specific antigen PSA response rates. Participants undergo regular assessments including safety evaluations and pharmacokinetic sampling. The total study duration may last up to approximately two years after the final dose.